KRAS and BRAF Mutation Spectrum In 1,035 FFPE Tumor Samples Submitted For Clinical Testing


Ryan P. Bender, Matthew J. McGinniss, Liza Dejesa-Jamanila and Christine Jamanila, and Christine Kuslich

Clinical guidelines have recommended that KRAS mutational status be determined in all patients with metastatic colorectal cancer that are being considered for anti‐EGFR therapies.

• ~40% of colorectal samples were positive for KRAS mutations
• The most common mutation observed in KRAS was p.G12D
• 4.6% of all mutations observed in KRAS

Download Publication